These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23539538)

  • 41. Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation.
    Westerberg CM; Hägglund H; Nilsson G
    Cell Death Dis; 2012 Nov; 3(11):e417. PubMed ID: 23152053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.
    Peter B; Winter GE; Blatt K; Bennett KL; Stefanzl G; Rix U; Eisenwort G; Hadzijusufovic E; Gridling M; Dutreix C; Hoermann G; Schwaab J; Radia D; Roesel J; Manley PW; Reiter A; Superti-Furga G; Valent P
    Leukemia; 2016 Feb; 30(2):464-72. PubMed ID: 26349526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.
    Gabillot-Carré M; Lepelletier Y; Humbert M; de Sepuvelda P; Hamouda NB; Zappulla JP; Liblau R; Ribadeau-Dumas A; Machavoine F; Letard S; Baude C; Hermant A; Yang Y; Vargaftig J; Bodemer C; Morelon E; Lortholary O; Recher C; Laurent G; Dy M; Arock M; Dubreuil P; Hermine O
    Blood; 2006 Aug; 108(3):1065-72. PubMed ID: 16597595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation.
    Bai Y; Bandara G; Ching Chan E; Maric I; Simakova O; Bandara SN; Lu WP; Wise SC; Flynn DL; Metcalfe DD; Gilfillan AM; Wilson TM
    Leukemia; 2013 Feb; 27(2):278-85. PubMed ID: 22907049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
    Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
    Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
    Verstovsek S; Akin C; Manshouri T; Quintás-Cardama A; Huynh L; Manley P; Tefferi A; Cortes J; Giles FJ; Kantarjian H
    Leuk Res; 2006 Nov; 30(11):1365-70. PubMed ID: 16797704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
    Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
    Front Immunol; 2018; 9():631. PubMed ID: 29643855
    [TBL] [Abstract][Full Text] [Related]  

  • 49. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.
    Schwaab J; Umbach R; Metzgeroth G; Naumann N; Jawhar M; Sotlar K; Horny HP; Gaiser T; Hofmann WK; Schnittger S; Cross NC; Fabarius A; Reiter A
    Am J Hematol; 2015 Sep; 90(9):774-7. PubMed ID: 26017288
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
    Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
    Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
    Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
    Gotlib J; Kluin-Nelemans HC; George TI; Akin C; Sotlar K; Hermine O; Awan FT; Hexner E; Mauro MJ; Sternberg DW; Villeneuve M; Huntsman Labed A; Stanek EJ; Hartmann K; Horny HP; Valent P; Reiter A
    N Engl J Med; 2016 Jun; 374(26):2530-41. PubMed ID: 27355533
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
    Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
    Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. C-kit mutations determine dasatinib mechanism of action in HMC-1 neoplastic mast cells: dasatinib differently regulates PKCδ translocation in HMC-1(560) and HMC-1(560,816) cell lines.
    Tobío A; Alfonso A; Botana LM
    Immunopharmacol Immunotoxicol; 2015; 37(4):380-7. PubMed ID: 26181649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Capitalizing on paradoxical activation of the mitogen-activated protein kinase pathway for treatment of Imatinib-resistant mast cell leukemia.
    Wilhelm T; Toledo MAS; Simons I; Stuth C; Mohta V; Mülfarth R; Nitsche M; Maschke-Neuß K; Schmitz S; Kaiser A; Panse J; Christen D; Arock M; Zenke M; Huber M
    Hematol Oncol; 2023 Aug; 41(3):520-534. PubMed ID: 36383121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KIT mutations in mastocytosis and their potential as therapeutic targets.
    Gotlib J
    Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.
    Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini RM; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
    EBioMedicine; 2019 May; 43():150-158. PubMed ID: 30975542
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.
    Mayerhofer M; Gleixner KV; Hoelbl A; Florian S; Hoermann G; Aichberger KJ; Bilban M; Esterbauer H; Krauth MT; Sperr WR; Longley JB; Kralovics R; Moriggl R; Zappulla J; Liblau RS; Schwarzinger I; Sexl V; Sillaber C; Valent P
    J Immunol; 2008 Apr; 180(8):5466-76. PubMed ID: 18390729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. KIT Mutations and Other Genetic Defects in Mastocytosis: Implications for Disease Pathology and Targeted Therapies.
    Chantran Y; Valent P; Arock M
    Immunol Allergy Clin North Am; 2023 Nov; 43(4):651-664. PubMed ID: 37758404
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.
    Fritsche-Polanz R; Fritz M; Huber A; Sotlar K; Sperr WR; Mannhalter C; Födinger M; Valent P
    Mol Oncol; 2010 Aug; 4(4):335-46. PubMed ID: 20471335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.